In addition to confirming the effects of newer agents on primary outcomes, significant reductions in hospital admissions were observed for (1) uncontrolled diabetes and long-term diabetes complications among patients who received all three newer diabetes second-line agents; (2) myocardial infarction, stroke, kidney disease, and diabetic nephropathy among those who received SGLT2i and GLP-1-RA; and (3) heart failure among those who received DPP-4i and SGLT2i. This evidence concerns the gene GLP1R and Stroke.